CAS 480452-36-6 Edoxaban Intermediate GMP condition

CAS : 480452-36-6 Edoxaban Intermediate GMP condition

Chemical Name : tert - butyl [ ( 1R , 2S , 5S ) - 2 - ( { [ ( 5 - chloropyridin - 2 - yl ) amino ] ( oxo ) acetyl } amino ) - 5 - ( dimethylaminocarbonyl ) cyclohexyl ] carbamate

CAS No . : 480452-36-6

Synonyms :  tert - Butyl ( 1R , 2S , 5S ) - 2 - ( { 2 - [ ( 5 - chloropyridin - 2 - yl ) amino ] - 2 - oxoacetyl } amino ) - 5 - [ ( dimethylamino ) carbonyl ] cyclohexyl - carbamate ; N1 - ( 5 - chloropyridin - 2 - yl ) - N2 - ( ( 1S , 2R , 4S ) - 2 - [ ( tert - butoxycarbonyl ) amino ] - 4 - [ ( dimethylamino ) carbonyl ] - cyclohexyl ) oxalamide

Molecular Formula : C21H30ClN5O5

Molecular Weight : 467.95

Usage : Edoxaban Intermediate

Description: Edoxaban is the active pharmaceutical ingredient (API) of branded drug Savaysa or Lixiana. The innovator of Edoxaban is a Japanese company called Daiichi Sankyo. Edeoxaban was approved in 2011 in Japan and by FDA in USA in 2015. Edoxaban is an anticoagulant drug for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). The patients with nonvalvular atrial fibrillation (NVAF) use it to reduce the risk of systemic embolism (SE) and stroke.

tert - butyl [ ( 1R , 2S , 5S ) - 2 - ( { [ ( 5 - chloropyridin - 2 - yl ) amino ] ( oxo ) acetyl } amino ) - 5 - ( dimethylaminocarbonyl ) cyclohexyl ] carbamate CAS No . : 480452-36-6 is one of its intermediates. Edoxaban is protected by some patents in some countries and areas such as USA, Europe and China. We strictly obey the laws and our product is only for R&D purpose. The buyers should determine the patent status and take the risks of patent infringement by themselves.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.